{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:38:08Z","timestamp":1761100688481},"reference-count":36,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2004,2,1]],"date-time":"2004-02-01T00:00:00Z","timestamp":1075593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2004,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The protease inhibitor saquinavir was administered to 100 human immunodeficiency virus type 1 (HIV-1)-infected patients as a single 600-mg oral dose (hard gelatin capsules) with a standard breakfast, including 200 ml of grapefruit juice, during an open-label trial to assess whether diarrhea and\/or wasting syndrome has consequences on its pharmacokinetics. Three groups of patients were enrolled: group 1, asymptomatic patients (\n            <jats:italic>n<\/jats:italic>\n            = 30); group 2, AIDS symptomatic patients without body weight loss or diarrhea (\n            <jats:italic>n<\/jats:italic>\n            = 37); and group 3, AIDS symptomatic patients with severe body weight loss and\/or diarrhea (\n            <jats:italic>n<\/jats:italic>\n            = 33). Clinical and biological data (covariates) were collected. A population approach was performed with three blood samples per patient to estimate the mean population pharmacokinetic parameters (clearance [CL]\/oral bioavailability [F],\n            <jats:italic>V<\/jats:italic>\n            \/F,\n            <jats:italic>k<\/jats:italic>\n            <jats:sub>a<\/jats:sub>\n            , and lag time) and the derived ones (\n            <jats:italic>k<\/jats:italic>\n            <jats:sub>el<\/jats:sub>\n            ,\n            <jats:italic>C<\/jats:italic>\n            <jats:sub>max<\/jats:sub>\n            ,\n            <jats:italic>T<\/jats:italic>\n            <jats:sub>max<\/jats:sub>\n            , and area under the curve [AUC]). The relationships between groups, exposure (i.e., estimated individual post hoc AUCs), and covariates were explored by using multiple linear regressions. A significant increase in median AUCs (165, 349, and 705 ng\u2009\u00b7\u2009h\u2009\u00b7\u2009ml\n            <jats:sup>\u22121<\/jats:sup>\n            for groups 1, 2, and 3, respectively [\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.0001]) was observed. The enhancement in saquinavir exposure could be due to the destruction of the transporters in enterocytes and\/or to the enlargement of their tight junctions, allowing a paracellular crossing of saquinavir as the illness spreads. Because of grapefruit juice intake by every patient, no implication of CYP3A4 could be assessed. These results strongly suggest that, despite its low intrinsic oral bioavailability, saquinavir can be considered as a relevant treatment for HIV-1-infected patients with diarrhea and\/or wasting syndrome. This must be evaluated in a long-term period.\n          <\/jats:p>","DOI":"10.1128\/aac.48.2.538-545.2004","type":"journal-article","created":{"date-parts":[[2004,1,24]],"date-time":"2004-01-24T23:46:39Z","timestamp":1074987999000},"page":"538-545","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":18,"title":["Enhanced Saquinavir Exposure in Human Immunodeficiency Virus Type 1-Infected Patients with Diarrhea and\/or Wasting Syndrome"],"prefix":"10.1128","volume":"48","author":[{"given":"Herve\u0301","family":"Trout","sequence":"first","affiliation":[{"name":"Laboratoire de Toxicologie et Pharmacologie Clinique, Service de Pharmacie"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"France","family":"Mentre\u0301","sequence":"additional","affiliation":[{"name":"INSERM E0357, De\u0301partement d'Epide\u0301miologie, Biostatistique et Recherche Clinique, Ho\u0302pital Bichat-Claude Bernard"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavie\u0300re","family":"Panhard","sequence":"additional","affiliation":[{"name":"INSERM E0357, De\u0301partement d'Epide\u0301miologie, Biostatistique et Recherche Clinique, Ho\u0302pital Bichat-Claude Bernard"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alissi","family":"Kodjo","sequence":"additional","affiliation":[{"name":"Unite\u0301 de Recherches The\u0301rapeutiques, Ho\u0302pital Lariboisie\u0300re"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Le\u0301lia","family":"Escaut","sequence":"additional","affiliation":[{"name":"Service des Maladies Infectieuses, Ho\u0302pital Paul Brousse, AP-HP, Villejuif, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Pernet","sequence":"additional","affiliation":[{"name":"Laboratoire de Biochimie A, Ho\u0302pital Saint-Antoine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Ge\u0301rard","family":"Gobert","sequence":"additional","affiliation":[{"name":"Service de Coprologie Fonctionnelle, Ho\u0302pital de la Pitie\u0301-Salpe\u0302trie\u0300re, AP-HP, Paris"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Vittecoq","sequence":"additional","affiliation":[{"name":"Service des Maladies Infectieuses, Ho\u0302pital Paul Brousse, AP-HP, Villejuif, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Laure","family":"Knellwolf","sequence":"additional","affiliation":[{"name":"Unite\u0301 de Recherches The\u0301rapeutiques, Ho\u0302pital Lariboisie\u0300re"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Caulin","sequence":"additional","affiliation":[{"name":"Unite\u0301 de Recherches The\u0301rapeutiques, Ho\u0302pital Lariboisie\u0300re"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Franc\u0327ois","family":"Bergmann","sequence":"additional","affiliation":[{"name":"Unite\u0301 de Recherches The\u0301rapeutiques, Ho\u0302pital Lariboisie\u0300re"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"187","volume":"18","year":"1989","unstructured":"Akinbami, F. O., G. A. Brown, and A. S. McNeish. 1989. Intestinal permeability as a measure of small mucosal integrity: correlation with jejunal biopsy. Afr. J. Med. Med. Sci.18:187-192.","journal-title":"Afr. J. Med. Med. Sci."},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1023\/A:1011924314899","volume":"15","year":"1998","unstructured":"Alsenz, J., H. Steffen, and R. Alex. 1998. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers. Pharm. Res.15:423-428.","journal-title":"Pharm. Res."},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2165\/00003088-199732030-00003","volume":"32","year":"1997","unstructured":"Barry, M., S. Gibbons, D. Back, and F. Mulcahy. 1997. Protease inhibitors in patients with AIDS disease: clinically important pharmacokinetic considerations. Clin. Pharmacokinet.32:194-209.","journal-title":"Clin. Pharmacokinet."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0168-3659(99)00034-6","volume":"62","year":"1999","unstructured":"Benet, L. Z., T. Izumi, Y. Zhang, J. A. Silverman, and V. J. Wacher. 1999. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J. Control Release62:25-31.","journal-title":"J. Control Release"},{"key":"e_1_3_2_6_2","first-page":"418","volume":"46","year":"1998","unstructured":"Bobin, S., D. Bouhour, S. Durupt, A. Boibieux, V. Girault, and D. Peyramond. 1998. Importance of antiproteases in the treatment of microsporidia and\/or cryptosporidia infections in HIV-seropositive patients. Pathol. Biol.46:418-419.","journal-title":"Pathol. Biol."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s002280050199","volume":"51","year":"1996","unstructured":"Br\u00e9ant, V., B. Charpiat, J. M. Sab, P. Maire, and R. W. Jelliffe. 1996. How many patients and blood levels are necessary for population pharmacokinetic analysis? A study of a one-compartment model applied to cyclosporine. Eur. J. Clin. Pharmacol.51:283-288.","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1023\/A:1018893418971","volume":"42","year":"1997","unstructured":"Carlson, S. J., C. Webster, and R. M. Craig. 1997. Urinary recovery of lactulose compared to d-xylose absorption kinetics in HIV patients with diarrhea and weight loss. Dig. Dis. Sci.42:2599-2602.","journal-title":"Dig. Dis. Sci."},{"key":"e_1_3_2_9_2","first-page":"545","volume":"15","year":"1976","unstructured":"Cockcroft, D. W., and M. H. Gault. 1976. Predictive creatinine clearance from serum creatinine. Nephron15:545-553.","journal-title":"Nephron"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1136\/gut.31.3.317","volume":"31","year":"1990","unstructured":"Cummins, A. G., J. T. Labrooy, D. P. Stanley, M. Rowland, and D. J. C. Shearman. 1990. Quantitative histological study of enteropathy associated with HIV infection. Gut31:317-321.","journal-title":"Gut"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1046\/j.1365-2125.1999.00052.x","volume":"48","year":"1999","unstructured":"Eagling, V. A., L. Profit, and D. J. Back. 1999. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br. J. Clin. Pharmacol.48:543-552.","journal-title":"Br. J. Clin. Pharmacol."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/BF02090365","volume":"39","year":"1994","unstructured":"Ehrenpreis, E. D., S. J. Carlson, H. L. Boorstein, and R. M. Craig. 1994. Malabsorption and deficiency of vitamin B12 in HIV-infected patients with chronic diarrhea. Dig. Dis. Sci.39:2159-2162.","journal-title":"Dig. Dis. Sci."},{"key":"e_1_3_2_13_2","first-page":"256","volume":"25","year":"1997","unstructured":"Fitzsimmons, M. E., and J. M. Collins. 1997. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab. Dispos.25:256-266.","journal-title":"Drug Metab. Dispos."},{"key":"e_1_3_2_14_2","unstructured":"Gibaldi M. and D. Perrier. 1982. One-compartment model p. 1-43. In M. Dekker (ed.) Pharmacokinetics. Marcel Dekker Inc. New York N.Y."},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"619","DOI":"10.7326\/0003-4819-102-5-619","volume":"102","year":"1985","unstructured":"Gillin, J. S., M. Shike, N. Alcock, C. Urmacher, S. Krown, R. C. Kurtz, C. J. Lightdale, and S. J. Winawer. 1985. Malabsorption and mucosal abnormalities of the small intestine in the acquired immunodeficiency syndrome. Ann. Intern. Med.102:619-622.","journal-title":"Ann. Intern. Med."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199630040-00004"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3109\/00365529209011172","volume":"27","year":"1992","unstructured":"Hollander, D. 1992. The intestinal permeability barrier: a hypothesis as to its regulation and involvement in Crohn's disease. Scand. J. Gastroenterol.27:721-726.","journal-title":"Scand. J. Gastroenterol."},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1097\/00002030-199611000-00008","volume":"10","year":"1996","unstructured":"Kapembwa, M. S., S. C. Fleming, M. Orr, C. Wells, M. Bland, D. Back, and G. E. Griffin. 1996. Impaired absorption in patients with AIDS-related small intestinal disease. AIDS10:1509-1514.","journal-title":"AIDS"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1136\/gut.37.5.623","volume":"37","year":"1995","unstructured":"Keating, J., I. Bjarnason, S. Somasundaram, A. Macpherson, N. Francis, A. B. Price, D. Sharpstone, J. Smithson, I. S. Menzies, and B. G. Gazzard. 1995. Intestinal absorption capacity, intestinal permeability, and jejunal histology in HIV and their relation to diarrhea. Gut37:623-629.","journal-title":"Gut"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1023\/A:1011972230829","volume":"15","year":"1998","unstructured":"Kenyon, C. J., F. Brown, G. R. McClelland, and I. R. Wilding. 1998. The use of pharmacoscintigraphy to elucidate food effects observed with a novel protease inhibitor (saquinavir). Pharm. Res.15:417-422.","journal-title":"Pharm. Res."},{"key":"e_1_3_2_21_2","first-page":"1439","volume":"286","year":"1998","unstructured":"Kim, A. E., J. M. Dintaman, D. S. Waddel, and J. A. Silverman. 1998. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J. Pharmacol. Exp. Ther.286:1439-1445.","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.7326\/0003-4819-101-4-421","volume":"101","year":"1984","unstructured":"Kotler, D. P., H. P. Gaetz, M. Lange, E. B. Klein, and P. R. Holt. 1984. Enteropathy associated with acquired immunodeficiency syndrome. Ann. Intern. Med.101:421-428.","journal-title":"Ann. Intern. Med."},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1046\/j.1365-2125.1998.t01-1-00687.x","volume":"45","year":"1998","unstructured":"Kupferschmidt, H. H., K. E. Fattinger, H. R. Ha, F. Follath, and S. Krahenbuhl. 1998. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br. J. Clin. Pharmacol.45:355-359.","journal-title":"Br. J. Clin. Pharmacol."},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3109\/00365529309096090","volume":"28","year":"1993","unstructured":"Lim, S. G., I. S. Menzies, C. A. Lee, M. A. Johnson, and R. E. Pounder. 1993. Intestinal permeability and function in patients infected with human immunodeficiency virus: a comparison with celiac disease. Scand. J. Gastroenterol.28:573-580.","journal-title":"Scand. J. Gastroenterol."},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1023\/A:1011583210549","volume":"28","year":"2001","unstructured":"Mentr\u00e9, F., C. Dubruc, and J. P. Th\u00e9not. 2001. Population pharmacokinetic analysis of mizolastine solution in children with optimization of the experimental design. J. Pharmacokinet. Pharmacodyn.28:299-319.","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/10543409508835104","volume":"5","year":"1995","unstructured":"Mentr\u00e9, F., and R. Gomeni. 1995. A two-step iterative algorithm for estimation in nonlinear mixed-effect models with an evaluation in population pharmacokinetics. J. Biopharm. Stat.5:141-158.","journal-title":"J. Biopharm. Stat."},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0306-5251.2001.01389.x"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00003495-199652010-00007","volume":"52","year":"1996","unstructured":"Noble, S., and D. Faulds. 1996. Saquinavir: a review of its pharmacology and clinical potential in the management of HIV infection. Drugs52:93-112.","journal-title":"Drugs"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365549850161430"},{"key":"e_1_3_2_30_2","first-page":"29","volume":"4","year":"1999","unstructured":"Pernet, P., D. Vittecoq, A. Kodjo, M. H. Randrianarisolo, L. Dumitrescu, H. Blondon, J. F. Bergmann, J. Giboudeau, and C. Aussel. 1999. Intestinal absorption and permeability in human immunodeficiency virus-infected patients. Scand. J. Gastroenterol.4:29-34.","journal-title":"Scand. J. Gastroenterol."},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1046\/j.1365-2125.1999.00919.x","volume":"47","year":"1999","unstructured":"Regazzi, M. B., P. Villani, R. Maserati, L. Cocchi, R. Giacchino, D. Burroni, and M. Rettani. 1999. Pharmacokinetic variability and strategy for therapeutic drug monitoring of saquinavir (SQN) in HIV-1-infected individuals. Br. J. Clin. Pharmacol.47:379-382.","journal-title":"Br. J. Clin. Pharmacol."},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0169-2607(00)00117-6","volume":"65","year":"2001","unstructured":"Retout, S., S. Duffull, and F. Mentr\u00e9. 2001. Development and implementation of the population Fisher information matrix for evaluation of population pharmacokinetic designs. Comp. Methods Programs Biomed.65:141-151.","journal-title":"Comp. Methods Programs Biomed."},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2000.tb05257.x"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1021\/js980082d","volume":"87","year":"1998","unstructured":"Wacher, V. J., J. A. Silverman, Y. Zhang, and L. Z. Benet. 1998. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci.87:1322-1330.","journal-title":"J. Pharm. Sci."},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199811010-00001"},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0169-409X(97)00041-0","volume":"27","year":"1997","unstructured":"Watkins, P. B. 1997. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv. Drug Deliv. Rev.27:161-170.","journal-title":"Adv. Drug Deliv. Rev."},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/BF00315553","volume":"44","year":"1993","unstructured":"Zorza, G., L. Beaugerie, A. M. Taburet, Y. Le Quintrec, and E. Singlas. 1993. Absorption of zidovudine in patients with diarrhoea. Eur. J. Clin. Pharmacol.44:501-503.","journal-title":"Eur. J. Clin. Pharmacol."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.48.2.538-545.2004","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.48.2.538-545.2004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:14:18Z","timestamp":1645467258000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.48.2.538-545.2004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,2]]}},"alternative-id":["10.1128\/AAC.48.2.538-545.2004"],"URL":"https:\/\/doi.org\/10.1128\/aac.48.2.538-545.2004","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,2]]},"assertion":[{"value":"2003-03-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-10-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-02-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}